8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


         Date of report (Date of earliest event reported): June 19, 2003


                         AMERICAN BIO MEDICA CORPORATION
             ------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

            New York                    0-28666                 14-1702188
           ---------                   --------                 ----------
(State or Other Jurisdiction   (Commission File Number)       (IRS Employer
      of Incorporation)                                  Identification Number)



               122 Smith Road, Kinderhook, NY                12106
               ---------------------------------------------------
               (Address of Principal Executive Offices) (Zip Code)

       Registrant's telephone number, including area code: (800) 227-1243











ITEM 5.  OTHER MATTERS

         On June 19, 2003, the Registrant's Board of Directors accepted the
resignation of D. Joseph Gersuk from the Registrant's Board of Directors. The
Registrant is unaware of any disagreement Mr. Gersuk has with the Registrant on
any matter relating to the Registrant's operations, policies or practices, nor
has Mr. Gersuk provided a letter outlining any such disagreements.

         On June 20, 2003, Donal V. Carroll was appointed to the Registrant's
Board of Directors. Mr. Carroll is president and managing director of Redbrook
Properties, a real estate investment company with holdings in Europe and North
America. Mr. Carroll will replace D. Joseph Gersuk on both the Registrant's
Audit and Compensation Committees.


ITEM 7.  FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS.

     (c) Exhibits.

         The following exhibits are filed with this report on Form 8-K:

         99.1 American Bio Medica Corporation press release dated June 23, 2003















                                       2





                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                           AMERICAN BIO MEDICA CORPORATION (Registrant)


Dated:  June 23, 2003      By:      Keith E. Palmer
                              --------------------------------------------------
                                    Keith E. Palmer
                                    Chief Financial Officer




















                                       3






                                                   Exhibit Index


Exhibit No.        Description                                         Page No.
- -----------        -----------                                         --------


     99.1          American Bio Medica Corporation press                  5
                   release dated June 23, 2003.




























                                      4

EX-99.1

                                                                    EXHIBIT 99.1


 FOR IMMEDIATE RELEASE:


              ABMC APPOINTS DONAL V. CARROLL TO BOARD OF DIRECTORS
                    New Director to Replace D. Joseph Gersuk

Kinderhook, N.Y., June 23, 2003 - American Bio Medica Corporation (NASDAQ: ABMC)
today announced the appointment of Donal V. Carroll to its board of directors.
Mr. Carroll is president and managing director of Redbrook Properties, a real
estate investment company with holdings in Europe and North America. Bringing
over 30 years of experience, Mr. Carroll's previous accomplishments include
founding and developing several successful finance and wholesale merchandising
companies. As an accomplished lawyer, Mr. Carroll also established a civil
rights defense practice which was the largest in Ireland for over a decade. He
will replace D. Joseph Gersuk, who resigned his position on the ABMC board on
June 19, 2003.

"We are pleased to welcome Donal Carroll to ABMC, and know that he brings with
him a wealth of entrepreneurial insights that will benefit our efforts," said
ABMC chairman and chief executive officer Gerald A. Moore. "At the same time, we
thank Joseph Gersuk for his contributions to the board, and wish him well in the
future."

About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops,
manufactures and markets accurate, cost-effective immunoassay diagnostic test
kits, including some of the world's most effective on-site drugs of abuse tests.
The company and its worldwide distribution network target the workplace,
government, corrections, clinical and educational markets. ABMC's Rapid Drug
Screen(R), Rapid One(R), Rapid Tec(R) and Rapid Tec Cup(TM) test for the
presence or absence of drugs of abuse in urine, while OralStat(R) tests for the
presence or absence of drugs of abuse in saliva. ABMC was recently named among
the 2002 Deloitte & Touche Technology Fast 500, a listing of the fastest-growing
technology companies in North America.

This release may contain forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results to
differ, and such differences could be material. Such risks and uncertainties
include, but are not limited to, the following: continued acceptance of the
Company's products, increased levels of competition in our industry, the
acceptance of new products, inherent risks associated with product development
and intellectual property rights, the Company's dependence on key personnel,
third party sales and suppliers. There can be no assurance that the Company will
be successful in addressing such risks and uncertainties. Investors are strongly
encouraged to review the section entitled "Risk Factors" in the Company's annual
report on Form 10-KSB for the fiscal year ended December 31, 2002, and quarterly
reports on Form 10-QSB on file with the Securities and Exchange Commission for a
discussion of risks and uncertainties that could affect operating results and
the market price of the Company's common shares.

                                      # # #



                                       5